Prospects for the development of vaccines against herpes simplex virus types 1 and 2 and other herpesvirus group vaccines are discussed from the scientific, medical, and economic standpoints. Probably, the most practical development will be glycoprotein subunit vaccines, prepared from herpes simples virus types 1 and 2, that will be tested for prophylaxis and therapy of acute viral disease and for cancer that may be caused by these agents.